Boehringer Ingelheim
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Boehringer Ingelheim sits in the top decile of US sponsors by registered trial count (#70 of 15,742 sponsors by registered trial count).
Boehringer Ingelheim: 515 sponsored US clinical trials, 43 recruiting.
Boehringer Ingelheim sponsors 515 registered US clinical trials on ClinicalTrials.gov, 43 of them currently recruiting, and 388 completed. 227 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 13 trials.
Top-decile sponsor footprint
Boehringer Ingelheim ranks in the top decile of sponsors by registered trial count (#70 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
388 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
515 total, page 4 of 11
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
NCT04423757
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
NCT04424290
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
NCT04399837
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
NCT04157751
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
NCT04552535
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
NCT04137289
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
NCT04223843
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
NCT04147247
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
NCT04093024
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
NCT04926233
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
NCT04147260
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
NCT04184297
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
NCT04138758
TARA Working Prototype Engagement Evaluation: Feasibility Study
NCT04085302
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
NCT04086121
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
NCT04059094
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
NCT04015518
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
NCT04002310
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
NCT03861234
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
NCT03964233
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03979807
Global Atrophie Biomarker Evaluation Study (GABiE)
NCT03935126
A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
NCT03820726
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia
NCT03859973
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
NCT03697304
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
NCT03835481
Impact of Tiotropium Add-on Therapy in Patients With Asthma
NCT03964220
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
NCT03842761
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
NCT03822832
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
NCT03958071
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
NCT03782792
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
NCT03659136
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT03717012
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
NCT03648541
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
NCT03635099
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
NCT03604445
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
NCT03468426
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03449381
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
NCT03482635
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
NCT03448406
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
NCT03429543
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
NCT03448419
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
NCT03385564
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
NCT03351244
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
NCT03313180
Real World Glycemic Effectiveness of Linagliptin
NCT03338803
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
NCT03157089
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
NCT03165227
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 143 |
| Phase 3 | 185 |
| Phase 4 | 42 |
Therapeutic Areas
What is open in the Boehringer Ingelheim pipeline
43 recruiting of 515 indexed (8% open); 388 completed (75%).
Phase mix: 227 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Pulmonary Disease, Chronic Obstructive (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boehringer Ingelheim: open-pipeline peers nationwide
Peers matched on 515 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boehringer Ingelheim sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 515 trials (± recruiting share)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 523 trials · 13% recruiting
- AbbVie · 526 trials · 21% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
Related
What to do with this Boehringer Ingelheim page
515 registered trials is a research-attention snapshot, not an endorsement of Boehringer Ingelheim or any single study.
- 43 of Boehringer Ingelheim's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition Boehringer Ingelheim studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Boehringer Ingelheim pipeline card: 515 registered trials from official public datasets.Report a data error.